Advertisement

Reduced susceptibility and resistance to bedaquiline in clinical M. tuberculosis isolates

Published:January 22, 2020DOI:https://doi.org/10.1016/j.jinf.2020.01.007

      Highlights

      • Elevated bedaquiline MIC is found in clinical M. tuberculosis isolates.
      • MIC change is driven by mutations in mmpR (rv0678) and atpE genes.
      • AtpE substitutions G25S, D28G, D28N, E61D, A63P, and A63V were observed in vivo.
      • Substitutions in codon 63 of AtpE were likely associated with a higher bedaquiline MIC.

      Abstract

      Objectives

      Bedaquiline is an effective drug used to treat MDR and XDR tuberculosis, providing high cure rates in complex therapy. Mutations in the mmpR (rv0678) and atpE genes are associated with reduced susceptibility to bedaquiline and have been identified in both in vitro selected strains and clinical isolates. However, the phenotypic criteria used to detect bedaquiline resistance have yet to be established due to the collection of few clinical isolates from patients receiving bedaquiline-containing treatment regimens.

      Methods

      One hundred eighty-two clinical isolates from 74 patients receiving bedaquiline and 163 isolates from 107 patients not exposed to bedaquiline were analysed. The bedaquiline MICs were tested using serial dilutions on 7H11 agar plates and the Bactec MGIT 960 system. The mmpR and atpE genes were sequenced by Sanger sequencing.

      Results

      The 7H11 agar method allowed for rapid discrimination between mutated and wild-type isolates and between exposed and non-exposed isolates. Seventy-three percent of bedaquiline-exposed isolates, as well as 91% of isolates with mutations, had an elevated bedaquiline MIC (≥ 0.12 mg/L on 7H11 media) compared to the reference isolates (89% had an MIC ≤ 0.03 mg/L). Previously reported in vitro-selected mutants (E61D and A63P) and novel AtpE substitutions (G25S and D28G) were observed in the clinical isolates. Substitutions in codon 63 of AtpE were likely associated with a higher bedaquiline MIC. Five new cases of pre-existing reduced susceptibility to bedaquiline, accompanied by mmpR mutations in most isolates, without a history of bedaquiline treatment were identified.

      Conclusions

      Bedaquiline treatment leads to an elevated bedaquiline MIC and the acquisition of mmpR and atpE gene mutations in tuberculosis strains. The standardisation of bedaquiline phenotypic susceptibility testing is urgently needed based on observed discrepancies between our study and previous studies and differences in solid and liquid media MIC determinations.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Infection
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Andries K.
        • Verhasselt P.
        • Guillemont J.
        • et al.
        A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.
        Science. 2005; 307: 223-227
        • Palomino J.C.
        • Martin A.
        TMC207 becomes bedaquiline, a new anti-TB drug.
        Future Microbiol. 2013; 8: 1071-1080
        • Diacon A.H.
        • Pym A.
        • Grobusch M.P.
        • et al.
        Multidrug-resistant tuberculosis and culture conversion with bedaquiline.
        N Engl J Med. 2014; 371: 723-732https://doi.org/10.1056/NEJMoa1313865
        • Borisov S.E.
        • Dheda K.
        • Enwerem M.
        • et al.
        Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
        Eur Respir J. 2017; 491700387
        • World Health Organization
        Rapid Communication : Key Changes to Treatment of Multidrug- and Rifampicin-Resistant Tuberculosis.
        WHO, 2018
        • Andries K.
        • Villellas C.
        • Coeck N.
        • et al.
        Acquired resistance of Mycobacterium tuberculosis to bedaquiline.
        PLoS One. 2014; 9e102135
        • Somoskovi A.
        • Bruderer V.
        • Hömke R.
        • et al.
        A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment.
        Eur Respir J. 2015; 45: 554-557
        • Bloemberg G V.
        • Keller P.M.
        • Stuckia D.
        • et al.
        Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis.
        N Engl J Med. 2015; 373: 1986-1988
        • Pym A.S.
        • Diacon A.H.
        • Tang S.J.
        • et al.
        Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
        Eur Respir J. 2016; 47: 564-574
        • Hoffmann H.
        • Kohl T.A.
        • Hofmann-Thiel S.
        • et al.
        Delamanid and bedaquiline resistance in mycobacterium tuberculosis ancestral beijing genotype causing extensively drug-resistant tuberculosis in a Tibetan refugee.
        Am J Respir Crit Care Med. 2016; 193: 337-340https://doi.org/10.1164/rccm.201502-0372LE
        • Veziris N.
        • Bernard C.
        • Guglielmetti L.
        • et al.
        Rapid emergence of mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors.
        Eur Respir J. 2017; 49 (pii: 1601719)https://doi.org/10.1183/13993003.01719-2016
        • Pang Y.
        • Zong Z.
        • Huo F.
        • et al.
        In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in beijing, china.
        Antimicrob Agents Chemother. 2017; 61 (pii: e00900-17)https://doi.org/10.1128/AAC.00900-17
        • Ismail N.A.
        • Omar S.V.
        • Joseph L.
        • et al.
        Defining bedaquiline susceptibility, resistance, cross-resistance and associated genetic determinants: a retrospective cohort study.
        EBioMedicine. 2018; 28: 136-142https://doi.org/10.1016/j.ebiom.2018.01.005
        • Polsfuss S.
        • Hofmann-Thiel S.
        • Merker M.
        • et al.
        Emergence of low-level delamanid and bedaquiline resistance during extremely drug-resistant tuberculosis treatment.
        Clin Infect Dis. 2019; (pii: ciz074)https://doi.org/10.1093/cid/ciz074
        • de Vos M.
        • Ley S.D.
        • Wiggins K.B.
        • et al.
        Bedaquiline microheteroresistance after cessation of tuberculosis treatment.
        N Engl J Med. 2019; 380: 2178-2180https://doi.org/10.1056/NEJMc1815121
        • De Jonge M.R.
        • Koymans L.H.M.
        • Guillemont J.E.G.
        • et al.
        A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910.
        Proteins Struct Funct Gene. 2007; 67: 971-980
        • Koul A.
        • Dendouga N.
        • Vergauwen K.
        • et al.
        Diarylquinolines target subunit c of mycobacterial ATP synthase.
        Nat Chem Biol. 2007; 3: 323-324
        • Preiss L.
        • Langer J.D.
        • Yildiz Ö.
        • et al.
        Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline.
        Sci Adv. 2015; 1e1500106
        • Hartkoorn R.C.
        • Uplekar S.
        • Cole S.T.
        Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis.
        Antimicrob Agents Chemother. 2014; 58: 2979-2981
        • Milano A.
        • Pasca M.R.
        • Provvedi R.
        • et al.
        Azole resistance in Mycobacterium tuberculosis is mediated by the Mmps5-Mmpl5 efflux system.
        Tuberculosis. 2009; 89: 84-90
        • Alexander D.C.
        • Vasireddy R.
        • Vasireddy S.
        • et al.
        Emergence of MmpT5 variants during bedaquiline treatment of Mycobacterium intracellulare lung disease.
        J Clin Microbiol. 2017; 55: 574-584
        • Li B.
        • Ye M.
        • Guo Q.
        • et al.
        Determination of MIC distribution and mechanisms of decreased susceptibility to bedaquiline among clinical isolates of Mycobacterium abscessus.
        Antimicrob Agents Chemother. 2018; 62 (e00175-18)
        • Zimenkov D.V.
        • Nosova E.Y.
        • Kulagina E.V.
        • et al.
        Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region.
        J Antimicrob Chemother. 2017; 72: 1901-1906
        • Almeida D.
        • Ioerger T.
        • Tyagi S.
        • et al.
        Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium tuberculosis.
        Antimicrob Agents Chemother. 2016; 60: 4590-4599
        • Köser C.U.
        • Maurer F.P.
        • Kranzer K.
        Those who cannot remember the past are condemned to repeat it’: drug-susceptibility testing for bedaquiline and delamanid.
        Int J Infect Dis. 2019; 80: S32-S35
      1. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. version 9.0. 2019.

        • World Health Organization
        Technical Report on Critical Concentrations for Drug Susceptibility Testing of Medicines used in the Treatment of Drug-Resistant Tuberculosis.
        WHO, 2018 (http://www.who.int/iris/handle/10665/260470)
      2. Siddiqi S.H., Rusch-Gerdes S.MGIT procedure manual for bactec mgit 960 TB system (Also applicable for manual MGIT) mycobacteria growth indicator tube (MGIT) culture and drug susceptibility demonstration projects. – 2006.

        • Clinical and Laboratory Standards Institute
        Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard – Second Edition: Document M24-A2.
        CLSI, Wayne, PA, USA2011
        • Rusch-Gerdes S.
        • Pfyffer G.E.
        • Casal M.
        • et al.
        Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials.
        J Clin Microbiol. 2006; 44: 688-692
        • Martinez E.
        • Hennessy D.
        • Jelfs P.
        • et al.
        Mutations associated with in vitro resistance to bedaquiline in Mycobacterium tuberculosis isolates in Australia.
        Tuberculosis. 2018; 111: 31-34
        • Van Altena R.
        • De Vries G.
        • Haar C.H.
        • et al.
        Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000–2009.
        Int J Tuberc Lung Dis. 2015; 19: 406-412
        • Diacon A.H.
        • Pym A.S.
        • Grobusch M.P.
        • et al.
        Multidrug-resistant tuberculosis and culture conversion with bedaquiline.
        N Engl J Med. 2014; 371: 723-732
        • Lovett S.T.
        Encoded errors: mutations and rearrangements mediated by misalignment at repetitive DNA sequences.
        Mol Microbiol. 2004; 52: 1243-1253
        • Villellas C.
        • Coeck N.
        • Meehan C.J.
        • et al.
        Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.
        J Antimicrob Chemother. 2017; 72: 684-690
        • Xu J.
        • Wang B.
        • Hu M.
        • et al.
        Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis.
        Antimicrob Agents Chemother. 2017; 61 (e00239-17)
        • Falzon D.
        • Schünemann H.J.
        • Harausz E.
        • et al.
        World health organization treatment guidelines for drug-resistant tuberculosis, 2016 update.
        Eur Respir J. 2017; 491602308
        • Torrea G.
        • Coeck N.
        • Desmaretz C.
        • et al.
        Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system.
        J Antimicrob Chemother. 2015; 70: 2300-2305
        • Veziris N.
        • Bernard C.
        • Guglielmetti L.
        • et al.
        Rapid emergence of mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors.
        Eur Respir J. 2017; 49 (pii: 1601719)https://doi.org/10.1183/13993003.01719-2016
        • Colangeli R.
        • Jedrey H.
        • Kim S.
        • et al.
        Bacterial factors that predict relapse after tuberculosis therapy.
        N Engl J Med. 2018; 379: 823-833https://doi.org/10.1056/NEJMoa1715849
        • Huitric E.
        • Verhasselt P.
        • Koul A.
        • Andries K.
        • Hoffner S.
        • Andersson D.I.
        Rates and mechanisms of resistance development in mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor.
        Antimicrob Agents Chemother. 2010; 54: 1022-1028
        • Segala E.
        • Sougakoff W.
        • Nevejans-Chauffour A.
        • et al.
        New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-Ring structure.
        Antimicrob Agents Chemother. 2012; 56: 2326-2334
        • Ismail N.
        • Omar S.V.
        • Ismail N.A.
        • et al.
        In vitro approaches for generation of Mycobacterium tuberculosis mutants resistant to bedaquiline, clofazimine or linezolid and identification of associated genetic variants.
        J Microbiol Methods. 2018; 153: 1-9
        • Sun G.
        • Luo T.
        • Yang C.
        • et al.
        Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients.
        J Infect Dis. 2012; 206: 1724-1733
        • Lenaerts A.
        • Barry C.E.
        • Dartois V.
        Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses.
        Immunol Rev. 2015; 264: 288-307
        • Meacci F.
        • Orrù G.
        • Iona E.
        • et al.
        Drug resistance evolution of a Mycobacterium tuberculosis strain from a noncompliant patient.
        J Clin Microbiol. 2005; 43: 3114-3120
        • Kundu S.
        • Biukovic G.
        • Grüber G.
        • et al.
        Bedaquiline targets the ε subunit of mycobacterial F-ATP synthase.
        Antimicrob Agents Chemother. 2016; 60: 6977-6979https://doi.org/10.1128/AAC.01291-16
        • Farhat M.R.
        • Freschi L.
        • Calderon R.
        • et al.
        GWAS for quantitative resistance phenotypes in Mycobacterium tuberculosis reveals resistance genes and regulatory regions.
        Nat Commun. 2019; 10: 2128https://doi.org/10.1038/s41467-019-10110-6
        • Ghajavand H.
        • Kargarpour Kamakoli M.
        • Khanipour S.
        • et al.
        High prevalence of bedaquiline resistance in treatment-naïve tuberculosis patients and verapamil effectiveness.
        Antimicrob Agents Chemother. 2019; 63 (e02530-18)
        • Kaniga K.
        • Cirillo D.M.
        • Hoffner S.
        • et al.
        A multilaboratory, multicountry study to determine bedaquiline MIC quality control ranges for phenotypic drug susceptibility testing.
        J Clin Microbiol. 2016; 54: 2956-2962
        • Rancoita P.M.V.
        • Cugnata F.
        • Gibertoni Cruz A.L.
        • et al.
        Validating a 14-drug microtiter plate containing bedaquiline and delamanid for large-scale research susceptibility testing of Mycobacterium tuberculosis.
        Antimicrob Agents Chemother. 2018; 62 (e00344–18)
        • Lounis N.
        • Vranckx L.
        • Gevers T.
        • et al.
        In vitro culture conditions affecting minimal inhibitory concentration of bedaquiline against M. tuberculosis.
        Med Mal Infect. 2016; 46: 220-225
        • Keller P.M.
        • Hömke R.
        • Ritter C.
        • et al.
        Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST.
        Antimicrob Agents Chemother. 2015; 59: 4352-4355https://doi.org/10.1128/AAC.00614-15